Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 24443

AbstractMaterial and MethodsResultsDiscussionConclusionReferencesDOI and Others
Article in PDF How to Cite Citation Manager Readers' Comments (0) Audio Visual Article Statistics Link to PUBMED Print this Article Send to a Friend
Advertisers Access Statistics Resources

Dr Mohan Z Mani

"Thank you very much for having published my article in record time.I would like to compliment you and your entire staff for your promptness, courtesy, and willingness to be customer friendly, which is quite unusual.I was given your reference by a colleague in pathology,and was able to directly phone your editorial office for clarifications.I would particularly like to thank the publication managers and the Assistant Editor who were following up my article. I would also like to thank you for adjusting the money I paid initially into payment for my modified article,and refunding the balance.
I wish all success to your journal and look forward to sending you any suitable similar article in future"



Dr Mohan Z Mani,
Professor & Head,
Department of Dermatolgy,
Believers Church Medical College,
Thiruvalla, Kerala
On Sep 2018




Prof. Somashekhar Nimbalkar

"Over the last few years, we have published our research regularly in Journal of Clinical and Diagnostic Research. Having published in more than 20 high impact journals over the last five years including several high impact ones and reviewing articles for even more journals across my fields of interest, we value our published work in JCDR for their high standards in publishing scientific articles. The ease of submission, the rapid reviews in under a month, the high quality of their reviewers and keen attention to the final process of proofs and publication, ensure that there are no mistakes in the final article. We have been asked clarifications on several occasions and have been happy to provide them and it exemplifies the commitment to quality of the team at JCDR."



Prof. Somashekhar Nimbalkar
Head, Department of Pediatrics, Pramukhswami Medical College, Karamsad
Chairman, Research Group, Charutar Arogya Mandal, Karamsad
National Joint Coordinator - Advanced IAP NNF NRP Program
Ex-Member, Governing Body, National Neonatology Forum, New Delhi
Ex-President - National Neonatology Forum Gujarat State Chapter
Department of Pediatrics, Pramukhswami Medical College, Karamsad, Anand, Gujarat.
On Sep 2018




Dr. Kalyani R

"Journal of Clinical and Diagnostic Research is at present a well-known Indian originated scientific journal which started with a humble beginning. I have been associated with this journal since many years. I appreciate the Editor, Dr. Hemant Jain, for his constant effort in bringing up this journal to the present status right from the scratch. The journal is multidisciplinary. It encourages in publishing the scientific articles from postgraduates and also the beginners who start their career. At the same time the journal also caters for the high quality articles from specialty and super-specialty researchers. Hence it provides a platform for the scientist and researchers to publish. The other aspect of it is, the readers get the information regarding the most recent developments in science which can be used for teaching, research, treating patients and to some extent take preventive measures against certain diseases. The journal is contributing immensely to the society at national and international level."



Dr Kalyani R
Professor and Head
Department of Pathology
Sri Devaraj Urs Medical College
Sri Devaraj Urs Academy of Higher Education and Research , Kolar, Karnataka
On Sep 2018




Dr. Saumya Navit

"As a peer-reviewed journal, the Journal of Clinical and Diagnostic Research provides an opportunity to researchers, scientists and budding professionals to explore the developments in the field of medicine and dentistry and their varied specialities, thus extending our view on biological diversities of living species in relation to medicine.
‘Knowledge is treasure of a wise man.’ The free access of this journal provides an immense scope of learning for the both the old and the young in field of medicine and dentistry as well. The multidisciplinary nature of the journal makes it a better platform to absorb all that is being researched and developed. The publication process is systematic and professional. Online submission, publication and peer reviewing makes it a user-friendly journal.
As an experienced dentist and an academician, I proudly recommend this journal to the dental fraternity as a good quality open access platform for rapid communication of their cutting-edge research progress and discovery.
I wish JCDR a great success and I hope that journal will soar higher with the passing time."



Dr Saumya Navit
Professor and Head
Department of Pediatric Dentistry
Saraswati Dental College
Lucknow
On Sep 2018




Dr. Arunava Biswas

"My sincere attachment with JCDR as an author as well as reviewer is a learning experience . Their systematic approach in publication of article in various categories is really praiseworthy.
Their prompt and timely response to review's query and the manner in which they have set the reviewing process helps in extracting the best possible scientific writings for publication.
It's a honour and pride to be a part of the JCDR team. My very best wishes to JCDR and hope it will sparkle up above the sky as a high indexed journal in near future."



Dr. Arunava Biswas
MD, DM (Clinical Pharmacology)
Assistant Professor
Department of Pharmacology
Calcutta National Medical College & Hospital , Kolkata




Dr. C.S. Ramesh Babu
" Journal of Clinical and Diagnostic Research (JCDR) is a multi-specialty medical and dental journal publishing high quality research articles in almost all branches of medicine. The quality of printing of figures and tables is excellent and comparable to any International journal. An added advantage is nominal publication charges and monthly issue of the journal and more chances of an article being accepted for publication. Moreover being a multi-specialty journal an article concerning a particular specialty has a wider reach of readers of other related specialties also. As an author and reviewer for several years I find this Journal most suitable and highly recommend this Journal."
Best regards,
C.S. Ramesh Babu,
Associate Professor of Anatomy,
Muzaffarnagar Medical College,
Muzaffarnagar.
On Aug 2018




Dr. Arundhathi. S
"Journal of Clinical and Diagnostic Research (JCDR) is a reputed peer reviewed journal and is constantly involved in publishing high quality research articles related to medicine. Its been a great pleasure to be associated with this esteemed journal as a reviewer and as an author for a couple of years. The editorial board consists of many dedicated and reputed experts as its members and they are doing an appreciable work in guiding budding researchers. JCDR is doing a commendable job in scientific research by promoting excellent quality research & review articles and case reports & series. The reviewers provide appropriate suggestions that improve the quality of articles. I strongly recommend my fraternity to encourage JCDR by contributing their valuable research work in this widely accepted, user friendly journal. I hope my collaboration with JCDR will continue for a long time".



Dr. Arundhathi. S
MBBS, MD (Pathology),
Sanjay Gandhi institute of trauma and orthopedics,
Bengaluru.
On Aug 2018




Dr. Mamta Gupta,
"It gives me great pleasure to be associated with JCDR, since last 2-3 years. Since then I have authored, co-authored and reviewed about 25 articles in JCDR. I thank JCDR for giving me an opportunity to improve my own skills as an author and a reviewer.
It 's a multispecialty journal, publishing high quality articles. It gives a platform to the authors to publish their research work which can be available for everyone across the globe to read. The best thing about JCDR is that the full articles of all medical specialties are available as pdf/html for reading free of cost or without institutional subscription, which is not there for other journals. For those who have problem in writing manuscript or do statistical work, JCDR comes for their rescue.
The journal has a monthly publication and the articles are published quite fast. In time compared to other journals. The on-line first publication is also a great advantage and facility to review one's own articles before going to print. The response to any query and permission if required, is quite fast; this is quite commendable. I have a very good experience about seeking quick permission for quoting a photograph (Fig.) from a JCDR article for my chapter authored in an E book. I never thought it would be so easy. No hassles.
Reviewing articles is no less a pain staking process and requires in depth perception, knowledge about the topic for review. It requires time and concentration, yet I enjoy doing it. The JCDR website especially for the reviewers is quite user friendly. My suggestions for improving the journal is, more strict review process, so that only high quality articles are published. I find a a good number of articles in Obst. Gynae, hence, a new journal for this specialty titled JCDR-OG can be started. May be a bimonthly or quarterly publication to begin with. Only selected articles should find a place in it.
An yearly reward for the best article authored can also incentivize the authors. Though the process of finding the best article will be not be very easy. I do not know how reviewing process can be improved. If an article is being reviewed by two reviewers, then opinion of one can be communicated to the other or the final opinion of the editor can be communicated to the reviewer if requested for. This will help one’s reviewing skills.
My best wishes to Dr. Hemant Jain and all the editorial staff of JCDR for their untiring efforts to bring out this journal. I strongly recommend medical fraternity to publish their valuable research work in this esteemed journal, JCDR".



Dr. Mamta Gupta
Consultant
(Ex HOD Obs &Gynae, Hindu Rao Hospital and associated NDMC Medical College, Delhi)
Aug 2018




Dr. Rajendra Kumar Ghritlaharey

"I wish to thank Dr. Hemant Jain, Editor-in-Chief Journal of Clinical and Diagnostic Research (JCDR), for asking me to write up few words.
Writing is the representation of language in a textual medium i e; into the words and sentences on paper. Quality medical manuscript writing in particular, demands not only a high-quality research, but also requires accurate and concise communication of findings and conclusions, with adherence to particular journal guidelines. In medical field whether working in teaching, private, or in corporate institution, everyone wants to excel in his / her own field and get recognised by making manuscripts publication.


Authors are the souls of any journal, and deserve much respect. To publish a journal manuscripts are needed from authors. Authors have a great responsibility for producing facts of their work in terms of number and results truthfully and an individual honesty is expected from authors in this regards. Both ways its true "No authors-No manuscripts-No journals" and "No journals–No manuscripts–No authors". Reviewing a manuscript is also a very responsible and important task of any peer-reviewed journal and to be taken seriously. It needs knowledge on the subject, sincerity, honesty and determination. Although the process of reviewing a manuscript is a time consuming task butit is expected to give one's best remarks within the time frame of the journal.
Salient features of the JCDR: It is a biomedical, multidisciplinary (including all medical and dental specialities), e-journal, with wide scope and extensive author support. At the same time, a free text of manuscript is available in HTML and PDF format. There is fast growing authorship and readership with JCDR as this can be judged by the number of articles published in it i e; in Feb 2007 of its first issue, it contained 5 articles only, and now in its recent volume published in April 2011, it contained 67 manuscripts. This e-journal is fulfilling the commitments and objectives sincerely, (as stated by Editor-in-chief in his preface to first edition) i e; to encourage physicians through the internet, especially from the developing countries who witness a spectrum of disease and acquire a wealth of knowledge to publish their experiences to benefit the medical community in patients care. I also feel that many of us have work of substance, newer ideas, adequate clinical materials but poor in medical writing and hesitation to submit the work and need help. JCDR provides authors help in this regards.
Timely publication of journal: Publication of manuscripts and bringing out the issue in time is one of the positive aspects of JCDR and is possible with strong support team in terms of peer reviewers, proof reading, language check, computer operators, etc. This is one of the great reasons for authors to submit their work with JCDR. Another best part of JCDR is "Online first Publications" facilities available for the authors. This facility not only provides the prompt publications of the manuscripts but at the same time also early availability of the manuscripts for the readers.
Indexation and online availability: Indexation transforms the journal in some sense from its local ownership to the worldwide professional community and to the public.JCDR is indexed with Embase & EMbiology, Google Scholar, Index Copernicus, Chemical Abstracts Service, Journal seek Database, Indian Science Abstracts, to name few of them. Manuscriptspublished in JCDR are available on major search engines ie; google, yahoo, msn.
In the era of fast growing newer technologies, and in computer and internet friendly environment the manuscripts preparation, submission, review, revision, etc and all can be done and checked with a click from all corer of the world, at any time. Of course there is always a scope for improvement in every field and none is perfect. To progress, one needs to identify the areas of one's weakness and to strengthen them.
It is well said that "happy beginning is half done" and it fits perfectly with JCDR. It has grown considerably and I feel it has already grown up from its infancy to adolescence, achieving the status of standard online e-journal form Indian continent since its inception in Feb 2007. This had been made possible due to the efforts and the hard work put in it. The way the JCDR is improving with every new volume, with good quality original manuscripts, makes it a quality journal for readers. I must thank and congratulate Dr Hemant Jain, Editor-in-Chief JCDR and his team for their sincere efforts, dedication, and determination for making JCDR a fast growing journal.
Every one of us: authors, reviewers, editors, and publisher are responsible for enhancing the stature of the journal. I wish for a great success for JCDR."



Thanking you
With sincere regards
Dr. Rajendra Kumar Ghritlaharey, M.S., M. Ch., FAIS
Associate Professor,
Department of Paediatric Surgery, Gandhi Medical College & Associated
Kamla Nehru & Hamidia Hospitals Bhopal, Madhya Pradesh 462 001 (India)
E-mail: drrajendrak1@rediffmail.com
On May 11,2011




Dr. Shankar P.R.

"On looking back through my Gmail archives after being requested by the journal to write a short editorial about my experiences of publishing with the Journal of Clinical and Diagnostic Research (JCDR), I came across an e-mail from Dr. Hemant Jain, Editor, in March 2007, which introduced the new electronic journal. The main features of the journal which were outlined in the e-mail were extensive author support, cash rewards, the peer review process, and other salient features of the journal.
Over a span of over four years, we (I and my colleagues) have published around 25 articles in the journal. In this editorial, I plan to briefly discuss my experiences of publishing with JCDR and the strengths of the journal and to finally address the areas for improvement.
My experiences of publishing with JCDR: Overall, my experiences of publishing withJCDR have been positive. The best point about the journal is that it responds to queries from the author. This may seem to be simple and not too much to ask for, but unfortunately, many journals in the subcontinent and from many developing countries do not respond or they respond with a long delay to the queries from the authors 1. The reasons could be many, including lack of optimal secretarial and other support. Another problem with many journals is the slowness of the review process. Editorial processing and peer review can take anywhere between a year to two years with some journals. Also, some journals do not keep the contributors informed about the progress of the review process. Due to the long review process, the articles can lose their relevance and topicality. A major benefit with JCDR is the timeliness and promptness of its response. In Dr Jain's e-mail which was sent to me in 2007, before the introduction of the Pre-publishing system, he had stated that he had received my submission and that he would get back to me within seven days and he did!
Most of the manuscripts are published within 3 to 4 months of their submission if they are found to be suitable after the review process. JCDR is published bimonthly and the accepted articles were usually published in the next issue. Recently, due to the increased volume of the submissions, the review process has become slower and it ?? Section can take from 4 to 6 months for the articles to be reviewed. The journal has an extensive author support system and it has recently introduced a paid expedited review process. The journal also mentions the average time for processing the manuscript under different submission systems - regular submission and expedited review.
Strengths of the journal: The journal has an online first facility in which the accepted manuscripts may be published on the website before being included in a regular issue of the journal. This cuts down the time between their acceptance and the publication. The journal is indexed in many databases, though not in PubMed. The editorial board should now take steps to index the journal in PubMed. The journal has a system of notifying readers through e-mail when a new issue is released. Also, the articles are available in both the HTML and the PDF formats. I especially like the new and colorful page format of the journal. Also, the access statistics of the articles are available. The prepublication and the manuscript tracking system are also helpful for the authors.
Areas for improvement: In certain cases, I felt that the peer review process of the manuscripts was not up to international standards and that it should be strengthened. Also, the number of manuscripts in an issue is high and it may be difficult for readers to go through all of them. The journal can consider tightening of the peer review process and increasing the quality standards for the acceptance of the manuscripts. I faced occasional problems with the online manuscript submission (Pre-publishing) system, which have to be addressed.
Overall, the publishing process with JCDR has been smooth, quick and relatively hassle free and I can recommend other authors to consider the journal as an outlet for their work."



Dr. P. Ravi Shankar
KIST Medical College, P.O. Box 14142, Kathmandu, Nepal.
E-mail: ravi.dr.shankar@gmail.com
On April 2011
Anuradha

Dear team JCDR, I would like to thank you for the very professional and polite service provided by everyone at JCDR. While i have been in the field of writing and editing for sometime, this has been my first attempt in publishing a scientific paper.Thank you for hand-holding me through the process.


Dr. Anuradha
E-mail: anuradha2nittur@gmail.com
On Jan 2020

Important Notice

Original article / research
Year : 2022 | Month : July | Volume : 16 | Issue : 7 | Page : DC22 - DC25 Full Version

Alarming Rise in Secondary Infections and Antimicrobial Resistance in COVID-19 Patients Admitted at a Tertiary Care Centre in Dehradun, Northern India


Published: July 1, 2022 | DOI: https://doi.org/10.7860/JCDR/2022/55872.16653
Rajender Singh, Nupur Koul, Manish Mittal, Barnali Kakati, Garima Mittal

1. Assistant Professor, Department of Neurology, Himalayan Institute of Medical Sciences, Dehradun, Uttrakhand, India. 2. Senior Resident, Department of Microbiology, Himalayan Institute of Medical Sciences, Dehradun, Uttarakhand, India. 3. Assistant Professor, Department of Microbiology, Himalayan Institute of Medical Sciences, Dehradun, Uttrakhand, India. 4. Professor, Department of Microbiology, Himalayan Institute of Medical Sciences, Dehradun, Uttarakhand, India. 5. Professor, Department of Microbiology, Himalayan Institute of Medical Sciences, Dehradun, Uttarakhand, India.

Correspondence Address :
Dr. Rajender Singh,
Department of Microbiology, Himalayan Institute of Medical Sciences, SRHU, Jollygrant, Dehradun, Uttrakhand, India.
E-mail: panwar.rajendra@gmail.com

Abstract

Introduction: Secondary infections are emerging as a serious threat among hospitalised patients of Coronavirus Disease-2019 (COVID-19). Overuse of antibiotics and inadequate infection control practices due to COVID-19 patients’ workload leads to a sudden upsurge of Multidrug Resistance (MDR) pathogens in healthcare settings attributing to higher mortality rates among the same.

Aim: To detect the secondary infection rate among COVID-19 patients admitted to the hospital ward and Intensive Care Unit (ICU), and report the impact on antimicrobial resistance and patient outcome.

Materials and Methods: A retrospective study was conducted for a period of three months of the second COVID-19 wave from 15th April 2021 to 14th july 2021 in the Department of Microbiology, Himalayan Institute of Medical Sciences (HIMS), Swami Rama Himalayan University (SRHU), Dehradun, Uttarakhand, India. All clinical samples of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) positive cases of COVID-19 received in the laboratory were cultured and identified using the Vitek-2 automated system and conventional fungal culture. Relevant demographic, characteristics, and clinical outcome data were obtained from records of the patient and recorded in reporting forms and were analysed for the study. Results were analysed with Statistical Package for the Social Sciences (SPSS) version 20.0 and Microsoft Excel 2019.

Results: Overall secondary infection rate of 135 (13.6%) was found among COVID-19 admitted patients. The most commonly isolated bacterial pathogens were Coagulase-negative Staphylococcus species (18.52%) and Enterococcus species (8.89%). Whereas the most common fungal isolates were Candida species (20.75%) and Rhizopus (8.15%). In the present study, 60.5% of bacterial pathogens isolated were Multidrug-resistant Organisms (MDRO). Mortality among COVID-19 patients with secondary infection was reported as 53% which was higher than the overall mortality rate of 36% in the same.

Conclusion: A high secondary infection rate, MDRO isolation rate, and high mortality among COVID-19 with secondary infection were reported. This shows the urgent need for reinforcement of infection control practices and strict antimicrobial stewardship policies.

Keywords

Antimicrobial stewardship policy, Multidrug resistant organisms, Secondary infections

Secondary infections due to varied aetiology such as bacterial, fungal, and viral are emerging as serious and undesirable consequences of hospitalisation in COVID-19 cases (1). In a meta-analyses around 23% of secondary infections are estimated for bacterial co-infection and secondary infection, along with increased mortality and morbidity (2),(3). A higher risk of secondary infections in COVID-19 patients is observed more commonly in critically ill ICU patients most probably due to viral-induced and drug-induced immunocompromised compromised state (4). Despite the high range of prevalence of secondary infection varying from 0.6-50% found in various studies done in China, the USA among these immunocompromised COVID-19 cases, they still appear as an understudied phenomenon (5),(7),(8),(9),(10),(11),(12),(13),(14),(15),(16),(17),(18),(19),(20).

During the current times of the pandemic, limited studies have been published on the stratification of admitted patients into different clinical settings and the bacterial and fungal aetiological profile of secondary infections in these patients (21),(22). An increasing number of COVID-19 patients were anticipatory put on empirical antimicrobial therapy in suspicion of the development of secondary infection (1). This empirical therapy is commonly guided by the Indian Council of Medical Research (ICMR) prepared from antibiogram data from various hospitals to prevent Healthcare Associated Infections (HAI) (1),(22). The émergence of drug-resistant pathogens causing bacterial and fungal infections is a hidden threat lurking among severe cases of this Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) virus-infected COVID-19 patients as 72% of COVID -19 patients received antimicrobial therapy without following proper antibiotic stewardship policy (21),(22). Amidst high workloads and resources primarily being allocated to COVID-19 diagnosis and management, antimicrobial stewardship efforts were undermined. Also, the use of empirical and broad-spectrum antimicrobial drugs leads to an increase in secondary infections due to MDRO in these patients. There was a decrease in the frequency of screening for carriage of MDROs as resources were focused on SARS-CoV-2 virus detection. These factors also contributed to increased rates of secondary infections in these severely ill patients (21),(23).

To meet this lacuna in the knowledge of the same and help understand the burden of secondary infections among COVID-19 patients, this study was aimed at detecting the secondary infection rate among COVID-19 patients admitted to our hospital and ICU and report the impact on antimicrobial resistance and patient outcome.

Material and Methods

A retrospective study data was collected for a period of three months between April 2021 and July 2021 and analysed in next two months from August 2021 to September 2021 in the Department of Microbiology, Himalayan Institute of Medical Sciences, Jolly grant after obtaining ethical approval from the Institutional Ethics Committee (IEC) no. ECR/483/Inst/UK/2013/RR-16 and proper informed written consent taken from the patients.

Sample size calculation: Convenience sampling method used for sample size calculation i.e. all samples received during these three months from suspected secondary infection from confirmed COVID-19 patients admitted to the hospital

Inclusion criteria: All clinical samples including Broncho Alveolar Lavage (BAL) fluid, sputum, urine, blood samples, and nasal crust received in microbiology laboratory from COVID-19 admitted patients with secondary pneumonia, urinary tract infection, bloodstream infections of unknown origin, and upper respiratory tract infection.

Exclusion criteria: All clinical samples received in the microbiology lab from admitted patients having infections other than COVID-19.

Data collection

All clinical samples received in the microbiology laboratory from COVID-19 patients (with an RT-PCR positive report for SARS CoV-2 virus) were included in the study according to inclusion criteria. Relevant demographic, characteristics, and clinical outcome data were obtained from records of the patient and recorded in the performed reporting forms.

Various clinical specimens of COVID-19 positive cases, were received from both wards (187 samples) as well as ICU (198 samples) for both bacterial and or fungal cultures. Clinical samples including BAL fluid, sputum, urine, blood samples, and nasal crust were received and processed immediately as per routine standard operating procedures. Samples received for bacterial cultures were subjected to gram staining and routine culture on Blood and MacConkey agars and incubated overnight at 37oC for isolation of pathogens. While samples received for fungal cultures were subjected to Potassium Hydroxide (KOH) mount and plated onto sabaroud’ dextrose agar. Isolates recovered were identified using Vitek-2 automated system. As this automated system uses a growth-based technology for identification and also provides Minimum Inhibitory Concentration (MIC) for antimicrobial susceptibility, it was used to identify and report the pathogens and their antimicrobial susceptibility profile.

Statistical Analayis

SPSS version 20.0 and Microsoft Excel 2019 were used for interpretation and analysis of obtained results. Qualitative data and quantitative data were expressed in terms of percentage and mean respectively.

Results

Out of 8630 sample tested, COVID positivity rate was 34.18% (2950/8630) asymptomatic were 1958 and symptomatic were 992. A total of 992 COVID-19 positive cases were admitted to our hospital and ICU during the study period and rest were sent to home isolation. A total of 385 out of 992 samples had suspected secondary infections with confirmed cases of COVID-19. A total of 135 isolates were recovered from these clinical samples from confirmed cases of COVID-19. An overall secondary infection rate of 13.6% was found which included a bacterial secondary infection rate of 7.2% and a fungal secondary infection rate of 6.4%. Male (64.4%) were more commonly associated with secondary infection in admitted COVID-19 patients as compared to females (35.6%) with a mean age of 52.5 years (Table/Fig 1). In this study, it was found that 32.9% of COVID-19 patients with secondary infections were admitted to the ICU whereas 8.2% were from the wards. (Table/Fig 1) also depicts that ICU admitted with COVID-19 patients (32.9%) were more frequently associated with secondary infection as compared to wards (8%). With two consecutive peaks of COVID-19 pandemic in 2020 and 2021, it has also been observed that 61% of MDR pathogenic isolates were seen in 2nd COVID-19 wave while 34% in 1st peak among COVID-19 admitted patients with SIs.

Most commonly pathogens were recovered from the nasal crust (57.6%) followed by blood cultures (29.4%) and urine (22.8%) (Table/Fig 2). Overall, Candida (20.75%) seems to be isolated from all clinical samples followed by CONS (18.52%) with the least frequent were Enterobacter and Pseudomonas (0.74%) (Table/Fig 3).

In the current study, mortality among COVID- 19 patients with secondary infection was 53% higher than the overall mortality rate of 36% in COVID-19 patients (Table/Fig 4). A higher mortality rate was found among ICU admitted COVID-19 patients with suspected secondary infections (64%) when compared to COVID-19 patients with suspected secondary infections admitted in wards (34%).

In this study, it has also been observed that, ampicillin (100%) was the most resistant antibiotic followed by drugs of cephalosporin’s class (avg. 96.4%), and linezolid (100%) was the most sensitive drug among the bacterial isolates (Table/Fig 5). About 43 (60.5%) out of the 71 bacterial isolates were found MDRO from all samples of COVID-19 patients with suspected secondary infections. A rise in MDRO causing infections was observed during the COVID-19 pandemic as compared to the preCOVID-19 era. 32% and 36.33% of multidrug-resistant strains were recovered in 2018 and 2019 respectively whereas, during the COVID era in the years 2020 and 2021, 49.20% and 46.43% MDROs were reported (Table/Fig 6).

Discussion

The existing literature available on secondary infections among COVID-19 patients is strongly suggestive of super-infections with varied aetiology globally. Various studies done in other countries like China, the USA, and Italy had variations in secondary infection rates ranging from 0.6-50% either bacterial, viral, or fungal aetiology. In two studies done in the USA, patients show 2.1% and 5.6 % SIs, and some Chinese studies show SIs ranging from 4.3-50% (7),(8),(9),(10),(11),(12),(13),(14),(15),(16),(17),(18),(19),(20). ICMR study done across 10 major hospitals shows an average of 3.6% secondary infections ranging from 0.4- to 28.5% (24). In present study, a secondary infection rate among admitted COVID-19 patients was 13.6%. A similar study from AIIMS, India reported a secondary infection rate of around 13% among severe cases of COVID-19 (1). In a study conducted at Wuhan, a 31% secondary rate was reported among ICU patients and a 10% secondary infection rate was reported overall (6). In a recent systematic review, the study reported a secondary infection rate ranging from 7-51%, especially in critically ill patients admitted to ICU infected with COVID-19 (25). In this present study, it was found that 32.9% of COVID-19 patients with secondary infections were admitted to the ICU whereas 8% were from the wards. In a similar study conducted in AIIMS hospital by Khurana S et al., 37% of COVID-19 patients who developed secondary infections were admitted to the ICU (1). A cumulative incidence of 50% of a patient admitted to ICU had ventilator-associated pneumonia and bloodstream infection were the second most common secondary infection observed ranging from 3.4-50% (26),(27),(28). In the present study also, it has been observed that the common system involved in secondary infection was the respiratory system (52.2%) followed by bloodstream infection (29.4%), this finding found also similar to the ICMR study with the same frequent system involvement (24).

This study found that majority of the pathogens recovered from clinical isolates of COVID-19 patients suspected to have secondary infections were multi-drug resistant. MDRO was found in around 60.5% of isolates. In a similar study, a 60% MDR isolation rate was found (29). In present study, an alarming rise in MDRO during the COVID-19 era including the data for 2020 and 2021 when compared with preCOVID years of 2018 and 2019. ICMR published data summaries a high antimicrobial resistance prevalence among Indian hospitals during even the preCOVID pandemic times. The alarming rise in antimicrobial resistance during the pandemic could be attributed to the increasing pressures to start empirical antimicrobials (30). Over-prescription and precautionary administration of antimicrobials in patients critically ill patients without bacterial infections was also a leading cause of the rise in antimicrobial resistance during this pandemic and admittedly reported by a group of European clinicians (31).

However, targeted antimicrobial therapy following culture over a prophylactic empirical therapy would allow for a de-escalassions of antimicrobiens and helps to reduce the burden of secondary as well as HAIs due to antimicrobial resistance strains among these critically ill patients.

In this study, an overall in-hospital mortality rate observed was 36% and 53% in COVID-19 admitted patients with a secondary infection which corresponds to an almost similar study done by Vijay S et al., stated that the mortality among ICU patients was 56.7% against overall mortality of 10.6% in total admitted COVID-19 patient. This means half of the COVID-19 patients who developed secondary infections have succumbed (24). It also has been observed that the proportion of mortality in ICU (64.3%) was found to be higher than inwards (35.7%) among COVID-19 patients with secondary infections. A similar study found 33% in-hospital mortality among ICU admitted COVID-19 patients with secondary infections (1). This higher involvement of secondary infection with COVID-19 and increasing MDR pathogen rates indicates the must necessitate of strict following of hospital infection control guidelines and antibiotic stewardship policy of the hospital and proper supervision by the government authorities over the injudicious or over the counter use of antibiotics.

Limitation(s)

Firstly, as it was a retrospective study, more prospective studies are needed to clarify the true picture of secondary infection and mortality involvement in COVID-19 patients admitted to the hospital. Secondly, molecular characterisation of drug resistant strains was not done in this study.

Conclusion

Increasing secondary infection rate in COVID-19 admitted patients and MDR isolates is a matter of concern. Fear of missing a secondary infection and lack of specific therapy for COVID-19 perhaps lead to an overprescription of antimicrobials. If promptly prioritised inwards and ICUs, reinforcing infection control practices and care bundles to prevent secondary infection could help reduce the burden. Sending appropriate and timely cultures, the use of biomarkers like procalcitonin and galactomannan, and antibiotic time-out at 48 hours of a prescription can help in reducing unnecessary antibiotic prescriptions.

It is our opinion that MDROs screening is the need of the hour as morbidity and mortality are substantially higher in secondary infections caused by them among COVID-19 cases. Appropriate infection control measures for MDROs if strongly implemented would help in reducing the burden of secondary infections and mortality rates in these cases.

References

1.
Khurana S, Singh P, Sharad N, Kiro VV, Rastogi N, Lathwal A, et al. Profile of co-infections & secondary infections in COVID-19 patients at a dedicated COVID-19 facility of a tertiary care Indian hospital: Implication on antimicrobial resistance. Indian J Med Microbiol. 2021;39(2):147-53. [crossref] [PubMed]
2.
Klein EY, Monteforte B, Gupta A, Jiang W, May L, Hsieh YH, et al. The frequency of influenza and bacterial coinfection: A systematic review and meta-analysis. Influenza Other Respir Viruses. 2016;10(5):394-03. [crossref] [PubMed]
3.
Joseph C, Togawa Y, Shindo N. Bacterial and viral infections associated with influenza. Influenza Other Respir Viruses. 2013;7:105-13. [crossref] [PubMed]
4.
De Bruyn A, Verellen S, Bruckers L, Geebelen L, Callebaut I, De Pauw I, et al. Secondary infection in COVID-19 critically ill patients: A retrospective single-center evaluation. BMC Infect Dis. 2022; 22(1):01-07. [crossref] [PubMed]
5.
Jancin B. Secondary infections common in COVID-19, implications unclear. MDEdge-Internal Med News. 2020.
6.
Kwon WJ, Li G, Zheng M, Kaur H, Magbual N, Dalai S. Superinfections and coinfections in COVID-19-separating the signal from the noise. Medpage Today. 2020;28.
7.
Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalised with COVID-19 in the New York City area. JAMA. 2020;323(20):2052-59. [crossref] [PubMed]
8.
Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med. 2020;382(24):2372-74. [crossref] [PubMed]
9.
Wu C, Chen X, Cai Y, Zhou X, Xu S, Huang H, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Int Med. 2020;180(7):934-43. [crossref] [PubMed]
10.
Kim D, Quinn J, Pinsky B, Shah NH, Brown I. Rates of co-infection between SARS-CoV-2 and other respiratory pathogens. JAMA. 2020; 323(20):2085-86. [crossref] [PubMed]
11.
Ding Q, Lu P, Fan Y, Xia Y, Liu M. The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China. J Med Virol. 2020;92(9):1549-55. [crossref] [PubMed]
12.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. The Lancet. 2020;395(10223):507-13. [crossref]
13.
Zangrillo A, Beretta L, Scandroglio AM, Monti G, Fominskiy E, Colombo S, et al. Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in Milan, Italy. Crit Care Resuscitation. 2020;22(3):200-11.
14.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497-06. [crossref]
15.
Li H, Chen K, Liu M, Xu H, Xu Q. The profile of peripheral blood lymphocyte subsets and serum cytokines in children with 2019 novel coronavirus pneumonia. J Infect. 2020;81(1):115-20. [crossref] [PubMed]
16.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-69. [crossref]
17.
Chen L, Liu HG, Liu W, Liu J, Liu K, Shang J, et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43:E005-05.
18.
Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020;323(16):1612-14. [crossref] [PubMed]
19.
Dong X, Cao YY, Lu XX, Zhang JJ, Du H, Yan YQ, et al. Eleven faces of coronavirus disease 2019. Allergy. 2020;75(7):1699-09. [crossref] [PubMed]
20.
Yu N, Li W, Kang Q, Xiong Z, Wang S, Lin X, et al. Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: A retrospective, single-centre, descriptive study. The Lancet infectious diseases. 2020;20(5):559-64. [crossref]
21.
Rawson TM, Moore LS, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and fungal coinfection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. 2020;71(9):2459-68. [crossref] [PubMed]
22.
Lai CC, Wang CY, Hsueh PR. Co-infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents? J Microbiol Immun Infect. 2020;53(4):505-12. [crossref] [PubMed]
23.
Indian Council of Medical Research. Annual report, Antimicrobial Resistance Surveillance Network, January 2017- 2017.
24.
Vijay S, Bansal N, Rao BK, Veeraraghavan B, Rodrigues C, Wattal C, et al. Secondary infections in hospitalized COVID-19 patients: Indian experience. Infect Druug Resis. 2021;14:1893. [crossref] [PubMed]
25.
Grasselli G, Cattaneo E, Florio G. Secondary infections in critically ill patients with COVID-19. Critical Care. 2021;25(1):01-06. [crossref] [PubMed]
26.
Rouzé A, Martin-Loeches I, Povoa P, Makris D, Artigas A, Bouchereau M, et al. 2021. Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: A European multicenter cohort study. Intensive Care Med. 2021;47(2):188-98. [crossref] [PubMed]
27.
Giacobbe DR, Battaglini D, Ball L, Brunetti I, Bruzzone B, Codda G, et al. Bloodstream infections in critically ill patients with COVID-19. European J Clin Investi. 2020;50(10):e13319. [crossref]
28.
Buetti N, Ruckly S, de Montmollin E, Reignier J, Terzi N, Cohen Y, et al. COVID-19 increased the risk of ICU-acquired bloodstream infections: A case-cohort study from the multicentric OUTCOMEREA network. Intensive Care Med. 2021;47(2):180-87. [crossref] [PubMed]
29.
Alison C. Incidence of Co-infection nosocomial infection. Massachusetts Gen. Hosp; 2020 [cited 2022 March 30].
30.
Huttner BD, Catho G, Pano-Pardo JR, Pulcini C, Schouten J. COVID-19: Don’t neglect antimicrobial stewardship principles! Clin Microbiol Infect. 2020;26(7):808-10. [crossref] [PubMed]
31.
EMJ Microbiol Infect Dis. 2022; DOI/10.33590/emjmicrobiolinfectdis/22E0607.https://doi.org/10.33590/emjmicrobiolinfectdis/22E0607.

DOI and Others

DOI: 10.7860/JCDR/2022/55872.16653

Date of Submission: Feb 24, 2022
Date of Peer Review: Mar 24, 2022
Date of Acceptance: May 20, 2022
Date of Publishing: Jul 01, 2022

AUTHOR DECLARATION:
• Financial or Other Competing Interests: None
• Was Ethics Committee Approval obtained for this study? Yes
• Was informed consent obtained from the subjects involved in the study? Yes
• For any images presented appropriate consent has been obtained from the subjects. NA

PLAGIARISM CHECKING METHODS:
• Plagiarism X-checker: Mar 02, 2022
• Manual Googling: May 05, 2022
• iThenticate Software: May 17, 2022 (4%)

ETYMOLOGY: Author Origin

JCDR is now Monthly and more widely Indexed .
  • Emerging Sources Citation Index (Web of Science, thomsonreuters)
  • Index Copernicus ICV 2017: 134.54
  • Academic Search Complete Database
  • Directory of Open Access Journals (DOAJ)
  • Embase
  • EBSCOhost
  • Google Scholar
  • HINARI Access to Research in Health Programme
  • Indian Science Abstracts (ISA)
  • Journal seek Database
  • Google
  • Popline (reproductive health literature)
  • www.omnimedicalsearch.com